NasdaqGS - Delayed Quote • USD
Assembly Biosciences, Inc. (ASMB)
At close: April 19 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -3.23 | -3.48 | -14.88 | -15.76 |
| Low Estimate | -3.23 | -3.48 | -14.88 | -15.76 |
| High Estimate | -3.23 | -3.48 | -14.88 | -15.76 |
| Year Ago EPS | -4.44 | -3.84 | -13.38 | -14.88 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | 7.16M | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -4.26 | -3.48 | -2.76 | -2.88 |
| EPS Actual | -4.44 | -3.84 | -3.24 | -2.15 |
| Difference | -0.18 | -0.36 | -0.48 | 0.73 |
| Surprise % | -4.20% | -10.30% | -17.40% | 25.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -3.23 | -3.48 | -14.88 | -15.76 |
| 7 Days Ago | -3.23 | -3.48 | -14.88 | -15.76 |
| 30 Days Ago | -3.24 | -3.48 | -14.76 | -13.56 |
| 60 Days Ago | -3.24 | -3.48 | -14.76 | -13.56 |
| 90 Days Ago | -0.27 | -0.29 | -1.23 | -1.13 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ASMB | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 27.30% | -- | -- | 1.60% |
| Next Qtr. | 9.40% | -- | -- | 10.50% |
| Current Year | -11.20% | -- | -- | 5.20% |
| Next Year | -5.90% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 17.00% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Neutral | 4/1/2024 |
Related Tickers
CTMX CytomX Therapeutics, Inc.
1.6700
-3.47%
SPRO Spero Therapeutics, Inc.
1.4000
-4.76%
NXTC NextCure, Inc.
1.6000
+1.91%
CLRB Cellectar Biosciences, Inc.
3.0300
-0.33%
GLPG.AS Galapagos NV
27.18
-0.73%
EIGRQ Eiger BioPharmaceuticals, Inc.
2.3900
+9.13%
TIL Instil Bio, Inc.
10.64
+3.30%
GLPG Galapagos NV
29.08
+0.59%
ALGS Aligos Therapeutics, Inc.
0.7500
-5.43%
ACHL Achilles Therapeutics plc
0.7829
-2.14%